Literature DB >> 18434142

Inhibitors of the tyrosine kinase EphB4. Part 1: Structure-based design and optimization of a series of 2,4-bis-anilinopyrimidines.

Catherine Bardelle1, Darren Cross, Sara Davenport, Jason G Kettle, Eun Jung Ko, Andrew G Leach, Andrew Mortlock, Jon Read, Nicola J Roberts, Peter Robins, Emma J Williams.   

Abstract

A series of bis-anilinopyrimidines have been identified as potent inhibitors of the tyrosine kinase EphB4. Structural information from two alternative series identified from screening efforts was combined to identify the initial leads.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18434142     DOI： 10.1016/j.bmcl.2008.04.015

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN： 0960-894X            Impact factor:   2.823


  18 in total

Review 1.  Targeting Eph receptors with peptides and small molecules: progress and challenges.

Authors:  Roberta Noberini; Ilaria Lamberto; Elena B Pasquale
Journal:  Semin Cell Dev Biol       Date:  2011-10-25       Impact factor: 7.727

2.  A novel benzodioxole-containing inhibitor of Toxoplasma gondii growth alters the parasite cell cycle.

Authors:  Edwin Kamau; Tracy Meehan; Mark D Lavine; Gustavo Arrizabalaga; Gabriela Mustata Wilson; Jon Boyle
Journal:  Antimicrob Agents Chemother       Date:  2011-09-26       Impact factor: 5.191

Review 3.  Eph receptors and ephrins in cancer: bidirectional signalling and beyond.

Authors:  Elena B Pasquale
Journal:  Nat Rev Cancer       Date:  2010-03       Impact factor: 60.716

Review 4.  Therapeutic targeting of EPH receptors and their ligands.

Authors:  Andrew W Boyd; Perry F Bartlett; Martin Lackmann
Journal:  Nat Rev Drug Discov       Date:  2014-01       Impact factor: 84.694

5.  Discovery of a novel chemotype of tyrosine kinase inhibitors by fragment-based docking and molecular dynamics.

Authors:  Hongtao Zhao; Jing Dong; Karine Lafleur; Cristina Nevado; Amedeo Caflisch
Journal:  ACS Med Chem Lett       Date:  2012-08-23       Impact factor: 4.345

Review 6.  EphB4: A promising target for upper aerodigestive malignancies.

Authors:  Ravi Salgia; Prakash Kulkarni; Prakash S Gill
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2018-01-31       Impact factor: 10.680

Review 7.  The status of isocyanide-based multi-component reactions in Iran (2010-2018).

Authors:  Ronak Afshari; Seyyed Emad Hooshmand; Mohammad Taghi Nazeri; Siamak Javanbakht; Ahmad Shaabani; Reza Mohammadian
Journal:  Mol Divers       Date:  2020-02-18       Impact factor: 2.943

8.  Structure-activity relationship study of EphB3 receptor tyrosine kinase inhibitors.

Authors:  Lixin Qiao; Sungwoon Choi; April Case; Thomas G Gainer; Kathleen Seyb; Marcie A Glicksman; Donald C Lo; Ross L Stein; Gregory D Cuny
Journal:  Bioorg Med Chem Lett       Date:  2009-09-09       Impact factor: 2.823

9.  Eph receptors and ephrin ligands: important players in angiogenesis and tumor angiogenesis.

Authors:  Birgit Mosch; Bettina Reissenweber; Christin Neuber; Jens Pietzsch
Journal:  J Oncol       Date:  2010-03-10       Impact factor: 4.375

10.  The small molecule specific EphB4 kinase inhibitor NVP-BHG712 inhibits VEGF driven angiogenesis.

Authors:  Georg Martiny-Baron; Philipp Holzer; Eric Billy; Christian Schnell; Joseph Brueggen; Mireille Ferretti; Niko Schmiedeberg; Jeanette M Wood; Pascal Furet; Patricia Imbach
Journal:  Angiogenesis       Date:  2010-08-29       Impact factor: 9.596
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.